Latest News
Conference Coverage
Treat-to-target strategy with tapering proves effective in PsA and axSpA
A trial showed for the first time that disease activity–guided treat-to-target tapering strategies in both psoriatic arthritis and axial...
Conference Coverage
Bimekizumab calms psoriatic arthritis in phase 3 ‘BE’ trials
The dual interleukin-17 inhibitor was effective both in patients for whom TNF inhibitors failed and those who had never received a biologic...
Conference Coverage
‘Shielding’ status provides best indicator of COVID-19 mortality in U.K. arthritis population
Shielding status was the highest ranked of all the risk factors identified for early mortality from COVID-19.
News
Upadacitinib earns FDA approval for ankylosing spondylitis
Janus kinase inhibitor offers oral option for patients who have who have had an insufficient response or intolerance with one or more tumor...
News
Trial gives new guidance for choosing initial PsA treatment
Adding the tumor necrosis factor inhibitor adalimumab to methotrexate because of a lack of efficacy or tolerability produced better results than...
News
Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasis
Survival rates were highest for rituximab in rheumatoid arthritis and golimumab in axial spondyloarthritis in a study of two Danish registries.
News
Methotrexate plus leflunomide proves effective for PsA
The combination therapy outperformed methotrexate monotherapy as a treatment option for patients with psoriatic arthritis (PsA), though it did...
News
FDA approves risankizumab (Skyrizi) for psoriatic arthritis
The approval is the second indication for the anti–interleukin-23 monoclonal antibody after clearance for plaque psoriasis was granted in 2019.
News
Proactive infliximab monitoring found best for sustaining control of inflammatory diseases
Proactive therapeutic drug monitoring with maintenance infliximab proved more effective in sustaining disease control than did standard care in...
Conference Coverage
Serious infection hospitalizations have declined in patients with PsA
Sepsis, urinary tract infections, and skin and soft-tissue infections declined among patients with PsA from 2012 to 2017 in the National Inpatient...